ValGenesis, a Santa Clara, CA-based provider of AI-powered digital validation solutions for the life sciences industry, has secured up to $16 million in strategic financing.
Investors
The financing was provided by the Innovation Banking Group at Bridge Bank, with backing from Morgan Stanley Expansion Capital.
Bridge Bank, a division of Western Alliance Bank (Member FDIC), delivers relationship-driven commercial banking solutions tailored to life sciences, technology, and innovation companies at all stages from startup to IPO. Founded in 2001 in Silicon Valley, the bank serves clients nationwide with specialized expertise and offices in key tech hubs. Bridge Bank also supports the private equity and venture capital sectors, as well as small to mid-sized Bay Area businesses.
ValGenesis Use of Funds
The company will use the funds to support product innovation in AI-assisted validation, global expansion, strategic hiring, regional partnerships, and enhanced customer success initiatives.
About ValGenesis
ValGenesis provides validation lifecycle management software solutions for regulated life sciences companies, pharmaceuticals, biotechnology, and medical devices. The company’s flagship solution, ValGenesis Smart GxP, is an AI-enabled platform purpose-built to unify validation and lifecycle management in regulated industries. Headquartered in Santa Clara, California, its platform unifies intelligent, risk-based validation and process automation in a connected ecosystem, streamlining operations, driving compliance, and reducing risk.
Funding Details
Company: ValGenesis Inc.
Raised: $16.0M
Round: Strategic Financing
Funding Date: July 2025
Lead Investor: Bridge Bank
Additional Investors: Morgan Stanley Expansion Capital
Company Website: https://www.valgenesis.com/
Software Category: Digital Validation Lifecycle Management / Life Sciences Tech
Source: https://www.businesswire.com/news/home/20250721367410/en/